CompletedNCT00167310
Omega-3 supplements for heart health in people with serious mental health conditions
About this title
Read the official source — NCT00167310Medication studyAges 18+United StatesSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 57
- Sponsor
- University of Pittsburgh
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00167310
- Official title
Show the full official title
CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Pittsburgh, a university.
Did this study involve medication?
Yes. The study involved medication, including Eicosapentaenoic acid (omega-3 fatty acid) and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
